Instrument Inactif

Communiqués Checkpoint Therapeutics Inc Other OTC

Actions

US1628281073

Recherche biotechnologique et médicale

Communiqués

13/05/25	Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates	AQ
29/04/25	CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT	BU
28/03/25	Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates	AQ
14/03/25	CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT	BU
16/12/24	Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT	AQ
16/12/24	Checkpoint Therapeutics : Announces FDA Approval of UNLOXCYTTM (cosibelimab ipdl) Form 8 K	PU
14/12/24	Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)	AQ
12/11/24	Checkpoint Therapeutics : Reports Third Quarter 2024 Financial Results and Recent Corporate Updates Form 8 K	PU
12/11/24	Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates	AQ
16/09/24	Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024	AQ
04/09/24	Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference	AQ
12/08/24	Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates	AQ
25/07/24	Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma	AQ
15/07/24	GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research	AQ
02/07/24	Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	AQ
02/07/24	Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab	AQ
24/06/24	Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission	AQ
13/05/24	Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates	AQ
13/05/24	Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference	AQ
10/05/24	Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates	AQ
25/03/24	Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	AQ
22/03/24	Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	AQ
18/03/24	Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors	AQ
29/01/24	Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market	AQ
11/01/24	Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference	AQ